Serial comparison of neointimal hyperplasia between the thin strut MiStent with microcrystalline sirolimus and the durable polymer coated everolimus-eluting Xience stent: 6- and 24-month results of DESSOLVE III OCT sub-study.
DESSOLVE III OCT sub-study compared serially neointimal hyperplasia volume obstruction (%VO) between the thin strut MiStent with early polymer elimination and 9-month sustained drug release from microcrystalline sirolimus and the durable polymer coated everolimus-eluting Xience stent at 6 and 24 months after implantation. The efficacy endpoint was %VO calculated as abluminal neointimal volume/stent volume. Thirty-six patients (MiStent 16 patients, 16 lesions, Xience 20 patients, 22 lesions) underwent serial OCT evaluation at both 6 and 24 months. At 6 months, mean abluminal %VO was significantly lower in the MiStent group than in Xience group (14.54±3.70% vs. 19.11±6.70%; p=0.011), whereas the difference in %VO between the two groups decreased at 24 months (20.88±5.72% vs. 23.50±7.33%; p=0.24). There was no significant difference in percentage malapposed struts and percentage uncovered struts between the two groups at both time points. In the serial comparative OCT analysis of the MiStent vs. the Xience, the MiStent showed a more favourable efficacy for preventing neointimal formation with comparable strut tissue coverage, as compared with the Xience at 6 months, but this difference in %VO decreased at 24 months so that the difference in neointima at 24 months was no longer significant.